At the time of writing, NewAmsterdam Pharma Company NV [NAMS] stock is trading at $35.95, down -1.48%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NAMS shares have gain 5.06% over the last week, with a monthly amount drifted -6.06%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo started tracking the stock with Overweight rating on August 25, 2025, and set its price target to $45. On July 17, 2025, Goldman initiated with a Neutral rating and assigned a price target of $27 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $42 on June 17, 2025. Stifel initiated its recommendation with a Buy and recommended $44 as its price target on June 10, 2025. Cantor Fitzgerald started tracking with a Overweight rating for this stock on June 04, 2025, and assigned it a price target of $42. In a note dated December 30, 2024, H.C. Wainwright initiated an Buy rating and provided a target price of $48 on this stock.
For the past year, the stock price of NewAmsterdam Pharma Company NV fluctuated between $14.06 and $42.00. Currently, Wall Street analysts expect the stock to reach $44.67 within the next 12 months. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $35.95 at the most recent close of the market. An investor can expect a potential return of 24.26% based on the average NAMS price forecast.
Analyzing the NAMS fundamentals
According to NewAmsterdam Pharma Company NV [NASDAQ:NAMS], the company’s sales were 35.24M for trailing twelve months, which represents an -98.80% plunge. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -5.76%, Pretax Profit Margin comes in at -6.27%, and Net Profit Margin reading is -6.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.29 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.50 points at the first support level, and at 35.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.67, and for the 2nd resistance point, it is at 37.39.
Ratios To Look Out For
It is important to note that NewAmsterdam Pharma Company NV [NASDAQ:NAMS] has a current ratio of 12.57. Also, the Quick Ratio is 12.57, while the Cash Ratio stands at 9.24. Considering the valuation of this stock, the price to sales ratio is 115.68, the price to book ratio is 5.59.
Transactions by insiders
Recent insider trading involved Louise Kooij, Officer, that happened on Dec 23 ’25 when 0.29 million shares were purchased. Former Affiliate, Bain Capital Life Sciences Fun completed a deal on Dec 02 ’25 to buy 0.27 million shares. Meanwhile, Former Affiliate BCLS II Investco, LP bought 4.5 million shares on Dec 02 ’25.
